Source comparison
Tesa Ipa vs CJC-1295/Ipamorelin: Blend Comparison
Tesa Ipa Tesamorelin (44 AA GHRH analogue) 26–38 minutes Ipamorelin (pentapeptide ghrelin mimetic) Daily Visceral fat reduction, lipodystrophy models, metabolic syndrome studies Short half-life GHRH requires daily dosing but avoids long-term receptor desensiti
This comparison does not assign a generated winner or score.
- Tesa Ipa
- Tesamorelin (44 AA GHRH analogue)
- 26–38 minutes
- Ipamorelin (pentapeptide ghrelin mimetic)
- Daily
- Visceral fat reduction, lipodystrophy models, metabolic syndrome studies
- Short half-life GHRH requires daily dosing but avoids long-term receptor desensitisation. Preferred for sustained multi-week protocols
- CJC-1295 (no DAC) / Ipamorelin
- CJC-1295 (modified GHRH analogue)
- ~30 minutes
- Ipamorelin
- Daily or twice daily
- General GH elevation studies, tissue repair models
- Nearly identical mechanism to Tesa Ipa with comparable half-life. Choice between the two often comes down to supplier formulation stability
- CJC-1295 (with DAC) / Ipamorelin
- CJC-1295 DAC (drug affinity complex extended)
- 6–8 days
- Weekly CJC dosing, daily ipamorelin
- Long-term GH elevation without daily injections
- Extended half-life reduces injection frequency but increases risk of receptor downregulation and blunted natural GH pulses over time
- GHRP-2 / Ipamorelin
- None (ghrelin-only protocol)
- N/A
- GHRP-2 + Ipamorelin
- Twice daily
- Appetite stimulation studies, cachexia models
- No upstream GHRH pathway activation. Relies entirely on ghrelin receptor saturation, which elevates cortisol and limits protocol duration
- The primary differentiator is half-life management. Tesamorelin's short half-life (under 40 minutes) means it clears quickly and doesn't suppress endogenous GHRH production the way long-acting analogues can. CJC-1295 without DAC operates nearly identically. The structural modifications in CJC extend stability slightly but not enough to change dosing. CJC-1295 with DAC (drug affinity complex) binds to serum albumin and extends the half-life to 6–8 days, allowing weekly dosing of the GHRH component while ipamorelin is still dosed daily. That protocol appeals to researchers prioritising convenience, but extended GHRH receptor occupation increases the risk of negative feedback suppression after 8–12 weeks.